-
The most recent HIV/AIDS statistics from the Centers for Disease Control and Prevention (CDC) show that HIV is the leading cause of death for African-Americans, ages 25-44, in the United States and the third leading cause of death for both African-Americans and Latinos in the 35-44 age group.
-
Several studies presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) have shown how HIV patients who are co-infected with hepatitis C are at greater risk for medical complications, including diabetes.
-
Guidelines released this year from the U.S. Department of Health and Human Services (DHHS) and the International AIDS Society-USA2 (IAS) recommend resistance testing for all recently infected patients beginning treatment.
-
Researchers and AIDS activists who have witnessed AIDSs destructive path across the world have nearly two decades of observations and data to show how the epidemic can be halted in countries where it begins primarily as an IDU (injection drug use/injection drug user) transmission problem.
-
The appearance of epileptic activity and etiologies of seizures vary with age. Anticonvulsant drug therapy optimally should stop seizure activity and prevent further brain injury that may later manifest as repeat spontaneous seizures or other neurodevelopmental injury. Since not all types of recurrent or persistent seizure activity are known to cause brain injury, the decision to treat must be individualized. Knowledgeable parents of children with known underlying disease and their pediatric neurologists can provide valuable information that can be integral in management decisions.
-
-
"EMTALA: The Essential Guide to Compliance" from Thomson American Health Consultants, publisher of "Pediatric Emergency Medicine Reports," explains how the changes to EMTALA will affect emergency departments and off-campus clinics.
-
To provide you with critical information on the updated regulations from the Centers for Medicare and Medicaid Services, Thomson American Health Consultants offers "New EMTALA Regulations: Are They Too Good to be True?" an audio conference on Tuesday, Oct. 21, from 2:30-3:30 p.m., ET.
-
The DANAMI-2 investigators, representing 29 hospitals and a patient base reflecting 62% of the Danish population, have reported on a trial assessing whether randomization to either fibrinolytic therapy or transport to an interventional facility results in differing major cardiovascular rates following acute ST elevation myocardial infarction (STEMI).
-
In hypertensive patients without clinically evident vascular disease, losartan was more effective than atenolol in preventing future vascular events independent of blood pressure control.
